4.6 Article

TGF-β-Mediated Downregulation of MicroRNA-196a Contributes to the Constitutive Upregulated Type I Collagen Expression in Scleroderma Dermal Fibroblasts

期刊

JOURNAL OF IMMUNOLOGY
卷 188, 期 7, 页码 3323-3331

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1100876

关键词

-

资金

  1. Japanese Ministry of Education, Science, Sports, and Culture
  2. Japanese Ministry of Health, Labor, and Welfare
  3. Grants-in-Aid for Scientific Research [23791280] Funding Source: KAKEN

向作者/读者索取更多资源

Previous reports indicated the significance of the TGF-beta signaling in the pathogenesis of systemic sclerosis. We tried to evaluate the possibility that microRNAs (miRNAs) play a part in the type I collagen upregulation seen in normal fibroblasts stimulated with exogenous TGF-beta and systemic sclerosis (SSc) fibroblasts. miRNA expression profile was evaluated by miRNA PCR array and real-time PCR. The protein expression of type I collagen was determined by immunoblotting. In vivo detection of miRNA in paraffin section was performed by in situ hybridization. Several miRNAs were found to be downregulated in both TGF-beta-stimulated normal fibroblasts and SSc fibroblasts compared with normal fibroblasts by PCR array. Among them, miR-196a expression was decreased in SSc both in vivo and in vitro by real-time PCR or in situ hybridization. In SSc fibroblasts, miR-196a expression was normalized by TGF-beta small interfering RNA. miR-196a inhibitor leads to the overexpression of type I collagen in normal fibroblasts, whereas overexpression of the miRNA resulted in the downregulation of type I collagen in SSc fibroblasts. In addition, miR-196a was detectable and quantitative in the serum of SSc patients. Patients with lower serum miR-196a levels had significantly higher ratio of diffuse cutaneous SSc: limited cutaneous SSc, higher modified Rodnan total skin thickness score, and higher prevalence of pitting scars than those without. miR-196a may play some roles in the pathogenesis of SSc. Investigation of the regulatory mechanisms of type I collagen expression by miR-196a may lead to new treatments using miRNA. The Journal of Immunology, 2012, 188: 3323-3331.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Dermatology

A Case of Pretibial Epidermolysis Bullosa with Novel Mutations of the COL7A1 Gene

Yuri Shimizu, Yorihisa Kotobuki, Noriko Arase, Hisashi Arase, Ichiro Katayama, Manabu Fujimoto

ANNALS OF DERMATOLOGY (2022)

Letter Dermatology

Clinical significance of maximum standardized uptake value of positron emission tomography/computed tomography as prognostic factor in extramammary Paget's disease

Yudo Kusaba, Ikko Kajihara, Soichiro Sawamura, Hisashi Kanemaru, Katsunari Makino, Jun Aoi, Shinichi Masuguchi, Jun Morinaga, Satoshi Fukushima

JOURNAL OF DERMATOLOGY (2022)

Article Biochemistry & Molecular Biology

Elevated Alpha 1(I) to Alpha 2(I) Collagen Ratio in Dermal Fibroblasts Possibly Contributes to Fibrosis in Systemic Sclerosis

Soichiro Sawamura, Katsunari Makino, Maho Ide, Shuichi Shimada, Ikko Kajihara, Takamitsu Makino, Masatoshi Jinnin, Satoshi Fukushima

Summary: In patients with systemic sclerosis (SSc), the levels of alpha 2(I) collagen are higher than alpha 1(I) collagen in fibroblasts. Further investigation of the overall regulatory mechanisms of type I collagen may help to understand the aberrant collagen metabolism in SSc.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Dermatology

Aggressive Squamous Cell Carcinoma in a Case of Epidermodysplasia Verruciformis Carrying a TMC6 Splice-site Mutation

Kazunori Yokoi, Noriko Arase, Takashi Shimbo, Manabu Fujimoto, Atsushi Tanemura

ACTA DERMATO-VENEREOLOGICA (2023)

Editorial Material Dermatology

Clues for developing next-generation cancer immunotherapy

Takashi Inozume, Satoshi Fukushima

EXPERIMENTAL DERMATOLOGY (2023)

Review Dermatology

Future prospects for cancer immunotherapy using induced pluripotent stem cell-derived dendritic cells or macrophages

Satoshi Fukushima, Azusa Miyashita, Haruka Kuriyama, Toshihiro Kimura, Satoru Mizuhashi, Yosuke Kubo, Satoshi Nakahara, Hisashi Kanemaru, Nobuhiro Tsuchiya, Hiroaki Mashima, Rong Zhang, Yasushi Uemura

Summary: Cancer immunotherapy is the primary treatment for unresectable cancers, but it is not a complete cure for all patients. Immune cell therapy, specifically using immune cells generated from induced pluripotent stem cells (iPSCs), shows promise for innovative cancer immunotherapy methods. iPSC-derived dendritic cells (iPS-DCs) can activate T cells, while iPSC-derived macrophages (iPS-MPs) attack cancer cells. iPSCs offer a source for genetic modification and addition of immune functions. Additionally, immortalized iPS-DCs and iPS-MPs could potentially reduce costs through mass production. This review summarizes the achievements and future prospects of cancer research using iPS-DCs and iPS-MPs.

EXPERIMENTAL DERMATOLOGY (2023)

Letter Dermatology

Elevation of cell-free DNA in patients with clinically amyopathic dermatomyositis

Tomohiro Ishino, Tselmeg Mijiddorj Myangat, Soichiro Sawamura, Ikko Kajihara, Shuichi Shimada, Hisashi Kanemaru, Kayo Kashiwada-Nakamura, Katsunari Makino, Shinichi Masuguchi, Satoshi Fukushima

JOURNAL OF DERMATOLOGY (2023)

Letter Dermatology

IL-10-Producing Potency from Blood B Cells Correlates with the Prognosis of Alopecia Areata

Yutaka Matsumura, Rei Watanabe, Hanako Koguchi-Yoshioka, Yuumi Nakamura, Aki Saito, Miki Kume, Shuichi Nakai, Yosuke Ishitsuka, Junichi Furuta, Manabu Fujimoto

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Article Dermatology

Gene-Modified Blister Fluid-Derived Mesenchymal Stromal Cells for Treating Recessive Dystrophic Epidermolysis Bullosa

Yasushi Kikuchi, Tomoki Tamakoshi, Ryuichi Ishida, Ryosuke Kobayashi, Shiho Mori, Akemi Ishida-Yamamoto, Manabu Fujimoto, Yasufumi Kaneda, Katsuto Tamai

Summary: In this study, researchers developed an ex vivo gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) using autologous mesenchymal stromal cells (MSCs). The gene-modified MSCs were injected into mice with type VII collagen deficiency, leading to continuous and widespread expression of type VII collagen. The therapy showed successful application in both early blistering skin and advanced ulcerative lesions in the RDEB mouse model.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Article Oncology

Increased anti-oxidative action compensates for collagen tissue degeneration in vitiligo dermis

Kazunori Yokoi, Yoshiaki Yasumizu, Naganari Ohkura, Koei Shinzawa, Daisuke Okuzaki, Nene Shimoda, Hideya Ando, Nanako Yamada, Manabu Fujimoto, Atsushi Tanemura

Summary: In this study, it was found that the skin tightness of hypopigmented lesions in vitiligo patients was more evident compared to uninvolved perilesional skin. Collagen homeostasis in vitiligo lesions appeared to be maintained despite the excessive oxidative stress associated with the disease. The expression of collagen-related genes and anti-oxidative enzymes was upregulated, collagen degeneration was attenuated, and the NRF2 signaling pathway was activated in vitiligo dermis.

PIGMENT CELL & MELANOMA RESEARCH (2023)

Editorial Material Rheumatology

A Combination of Autoantibodies Predicts the Fate of Cancer-Associated Dermatomyositis

Manabu Fujimoto

ARTHRITIS & RHEUMATOLOGY (2023)

Article Dermatology

Verification of the efficacy of topical sirolimus gel for systemic rare vascular malformations: a pilot study

Mari Wataya-Kaneda, Shinichirou Maeda, Ayumi Nakamura, Misa Hayashi, Manabu Fujimoto

Summary: A pilot study was conducted to evaluate the safety and efficacy of 0.2% sirolimus gel for venous and capillary malformations, and to compare its efficacy with systemic sirolimus treatment. The results showed that the gel was as clinically effective as systemic treatment and more effective for early active lesions, even systemic venous malformations.

JOURNAL OF DERMATOLOGY (2023)

Letter Dermatology

A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment

Chiaki Obaru, Toshihiro Kimura, Manami Yamamura, Haruka Kuriyama, Kayo Kashiwada-Nakamura, Satoru Mizuhashi, Tomoyo Matsumura, Takahiro Watanabe, Toshihiro Inoue, Satoshi Fukushima

JOURNAL OF DERMATOLOGY (2023)

Article Multidisciplinary Sciences

Deep intronic founder mutations identified in the ERCC4/XPF gene are potential therapeutic targets for a high- frequency form of xeroderma pigmentosum

Chikako Senju, Yuka Nakazawa, Taichi Oso, Mayuko Shimada, Kana Kato, Michiko Matsuse, Mariko Tsujimoto, Taro Masaki, Yasushi Miyazaki, Satoshi Fukushima, Satoshi Tateishi, Atsushi Utani, Hiroyuki Murota, Katsumi Tanaka, Norisato Mitsutake, Shinichi Moriwaki, Chikako Nishigori, Tomoo Ogi

Summary: Xeroderma pigmentosum (XP) is a rare genodermatosis characterized by photosensitivity and a high risk of skin tumors due to DNA repair deficiency. This study identified two deep intronic mutations in the ERCC4/XPF gene in 17 cases of XP-F, a rare subtype of XP. These mutations result in reduced gene expression and early-onset skin cancers, highlighting the need for attention to these variants. Additionally, antisense oligonucleotides designed for these mutations can restore DNA repair capacity, suggesting potential therapeutic targets for XP-F.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Review Immunology

Suppressive mechanisms of regulatory B cells in mice and humans

Yutaka Matsumura, Rei Watanabe, Manabu Fujimoto

Summary: B cells, including regulatory B cells (Bregs), regulate inflammation through an inhibitory mechanism mediated by interleukin 10 (IL-10). Bregs have been reported in various disease models and play a role in autoimmune diseases, infectious diseases, cancer, and organ-transplant rejection. In addition to IL-10, other cytokines and membrane-binding molecules are also involved in the suppressive functions of Bregs. The identification and classification of Breg fractions remains challenging due to the variations in their activity and differentiation stages in different disease models.

INTERNATIONAL IMMUNOLOGY (2023)

暂无数据